Aline. B. Sprikkelman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aline. B. Sprikkelman has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
- Gerard H. Koppelman
Department of Pediatric Pulmonology and Pediatric Allergology University of Groningen, University Medical Center Groningen, Beatrix Children's Hospital Groningen The Netherlands
6 shared publications - Arvid. W. A. Kamps
Department of Paediatrics Martini Hospital Groningen The Netherlands
5 shared publications - Wouter W. de Weger
Department of Paediatrics Martini Hospital Groningen The Netherlands
5 shared publications Catherina E. M. Herpertz
Department of Paediatrics Martini Hospital Groningen The Netherlands
3 shared publicationsGerbrich N. van der Meulen
Department of Pediatrics Martini Hospital Groningen The Netherlands
3 shared publicationsA.M.W. Bulk-Bunschoten
Vrije Universiteit medisch centrum/EMGO+, Amsterdam, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 12 August 2026
- Published by Springer Nature in Nature
- Vol. 658 (8134) , 218-229
Maternal influences on infant gut microbiome and health
The establishment of the infant gut microbiome is critical for later health 1,2 , yet how it is shaped by maternal and early-life factors remains unclear. Here we metagenomically sequenced 4,526 longitudinal faecal samples from 714 mother–infant pairs in the Dutch birth cohort Lifelines NEXT, spanning 12 weeks of pregnancy to 1 year postpartum. We integrated these data with 474 clinical and exposure variables, and with ultra-deep sequencing of breast milk and vaginal microbiomes. We observe that the maternal gut microbiome undergoes only subtle changes during pregnancy and postpartum, influenced by diet, infections and pre-pregnancy smoking. The maternal gut microbiome is a major reservoir for infant gut strains, with only occasional transmission from vaginal and breast milk microbiomes. Mother–infant gut strain sharing is time dependent, and higher maternal gut species abundance increases the likelihood of strain transmission. We find that the maternal gut microbiome is a predictor of infant eczema. Mode of delivery and feeding mode primarily shaped the infant gut microbiome and its functional profiles, with maternal exposures also having a role. Of 585 vaginally delivered infants, 155 were born at home, but home delivery was only moderately associated with infant gut microbiome composition, similar to other birth parameters such as duration of pushing and ruptured membranes. Overall, we highlight the central role of the mother and her microbiome in shaping the infant gut ecosystem and early health outcomes.
- 12 August 2026
- Published by Springer Nature in Nature
- Vol. 658 (8134) , 218-229
Open AccessMaternal influences on infant gut microbiome and health
The establishment of the infant gut microbiome is critical for later health 1,2 , yet how it is shaped by maternal and early-life factors remains unclear. Here we metagenomically sequenced 4,526 longitudinal faecal samples from 714 mother–infant pairs in the Dutch birth cohort Lifelines NEXT, spanning 12 weeks of pregnancy to 1 year postpartum. We integrated these data with 474 clinical and exposure variables, and with ultra-deep sequencing of breast milk and vaginal microbiomes. We observe that the maternal gut microbiome undergoes only subtle changes during pregnancy and postpartum, influenced by diet, infections and pre-pregnancy smoking. The maternal gut microbiome is a major reservoir for infant gut strains, with only occasional transmission from vaginal and breast milk microbiomes. Mother–infant gut strain sharing is time dependent, and higher maternal gut species abundance increases the likelihood of strain transmission. We find that the maternal gut microbiome is a predictor of infant eczema. Mode of delivery and feeding mode primarily shaped the infant gut microbiome and its functional profiles, with maternal exposures also having a role. Of 585 vaginally delivered infants, 155 were born at home, but home delivery was only moderately associated with infant gut microbiome composition, similar to other birth parameters such as duration of pushing and ruptured membranes. Overall, we highlight the central role of the mother and her microbiome in shaping the infant gut ecosystem and early health outcomes.
- Open Access
- 27 November 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (4) , 667-678
Multimorbidity and atopic dermatitis in a population-based cohort: severity-dependent association with distinct nonatopic multimorbidity patterns
Background: Atopic dermatitis (AD) has characteristics of a systemic disease due to underlying systemic inflammation, which is supported by reports of various comorbidities. Objectives: To examine the associations between AD and (nonatopic) multimorbidity in a population-based cohort from the northern Netherlands and to identify differences in multimorbidity patterns between participants with multimorbidity and no AD. Methods: We assessed the lifetime prevalence of 52 diseases, from 15 domains, combining data from questionnaires, medication records and clinical assessments within the Lifelines Cohort. Lifetime AD was self-reported, physician-diagnosed and disease severity based on the Patient-Oriented Eczema Measure. Multimorbidity was defined as the lifetime presence of at least two diseases, while nonatopic multimorbidity excluded asthma, rhinitis and food allergy. A composite morbidity score (cMS) indicated the degree of multimorbidity. We analysed associations of AD and AD severity with multimorbidity and cMS using binary and multinomial logistic regression, adjusting for age and sex, and additionally adjusting for socioeconomic and lifestyle factors. Patterns of nonatopic multimorbidity based on disease domains were explored using latent class analysis, stratified by AD presence. Results: Of 37 193 participants, 3242 (8.7%) had AD. The odds for nonatopic multimorbidity were 1.47-fold higher in participants with AD, particularly for those with moderate-to-severe disease (adjusted odds ratio 1.74 vs. 1.41 for mild disease). The association strengthened with higher degrees of nonatopic multimorbidity, reaching 2.09-fold for ≥ 5 diseases. When considering atopic diseases in the definition of multimorbidity and the cMS, the associations with AD were even stronger. Further adjustments for socioeconomic and lifestyle factors were corroborative. We identified five distinct multimorbidity classes among individuals with and without AD, with two differing across the groups. One class, characterized by the orofacial domain, was only present among those with AD, while another class – resembling the metabolic syndrome – had more of a respiratory contribution to AD with further differences regarding cardiometabolic involvement. Conclusions: Participants with AD, especially moderate-to-severe disease, are more likely to experience (nonatopic) multimorbidity and showed unique patterns of nonatopic multimorbidity with regard to orofacial and cardiometabolic diseases. Our findings highlight the importance of promoting awareness for interdisciplinary approaches to managing patients with AD. An author video to accompany this article is available online.
- 27 November 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (4) , 667-678
Open AccessMultimorbidity and atopic dermatitis in a population-based cohort: severity-dependent association with distinct nonatopic multimorbidity patterns
Background: Atopic dermatitis (AD) has characteristics of a systemic disease due to underlying systemic inflammation, which is supported by reports of various comorbidities. Objectives: To examine the associations between AD and (nonatopic) multimorbidity in a population-based cohort from the northern Netherlands and to identify differences in multimorbidity patterns between participants with multimorbidity and no AD. Methods: We assessed the lifetime prevalence of 52 diseases, from 15 domains, combining data from questionnaires, medication records and clinical assessments within the Lifelines Cohort. Lifetime AD was self-reported, physician-diagnosed and disease severity based on the Patient-Oriented Eczema Measure. Multimorbidity was defined as the lifetime presence of at least two diseases, while nonatopic multimorbidity excluded asthma, rhinitis and food allergy. A composite morbidity score (cMS) indicated the degree of multimorbidity. We analysed associations of AD and AD severity with multimorbidity and cMS using binary and multinomial logistic regression, adjusting for age and sex, and additionally adjusting for socioeconomic and lifestyle factors. Patterns of nonatopic multimorbidity based on disease domains were explored using latent class analysis, stratified by AD presence. Results: Of 37 193 participants, 3242 (8.7%) had AD. The odds for nonatopic multimorbidity were 1.47-fold higher in participants with AD, particularly for those with moderate-to-severe disease (adjusted odds ratio 1.74 vs. 1.41 for mild disease). The association strengthened with higher degrees of nonatopic multimorbidity, reaching 2.09-fold for ≥ 5 diseases. When considering atopic diseases in the definition of multimorbidity and the cMS, the associations with AD were even stronger. Further adjustments for socioeconomic and lifestyle factors were corroborative. We identified five distinct multimorbidity classes among individuals with and without AD, with two differing across the groups. One class, characterized by the orofacial domain, was only present among those with AD, while another class – resembling the metabolic syndrome – had more of a respiratory contribution to AD with further differences regarding cardiometabolic involvement. Conclusions: Participants with AD, especially moderate-to-severe disease, are more likely to experience (nonatopic) multimorbidity and showed unique patterns of nonatopic multimorbidity with regard to orofacial and cardiometabolic diseases. Our findings highlight the importance of promoting awareness for interdisciplinary approaches to managing patients with AD. An author video to accompany this article is available online.
- Open Access
Comparison of Double‐Blind and Open Food Challenges for the Diagnosis of Food Allergy in Childhood: The ALDORADO Study
Background: Double‐blind placebo‐controlled food challenge (DBPCFC) is widely regarded as the “gold standard” to diagnose food allergy. Maximum efforts are made to reduce bias, yet DBPCFCs are costly, time‐, and resource‐intensive. Less demanding open food challenges are increasingly used in clinical practice. However, recommendations regarding the use of these challenges are based on low certainty of evidence, and no comparative studies have been performed using the most recent international food challenge guidelines. We hypothesised that the open food challenge is non‐inferior to DBPCFC in children suspected of allergy to cashew nuts, hazelnuts or peanuts.Methods: A total of 63 children, aged 4 years and older, were included if referred for suspected IgE‐mediated allergy to cashew nut, hazelnut, or peanut. All study participants underwent DBPCFC first, followed by an open food challenge for the same food. Challenge outcomes were assessed by predefined criteria into positive, negative, or inconclusive.Results: DBPCFC and open food challenge outcomes were the same for 36/41 (87.8%) patients. Sensitivity and specificity of the open food challenge were 0.91 (95% CI 0.79, 1.03) and 0.83 (95% CI 0.63, 1.01), respectively, with an AUC value of 0.87. Eliciting and stop doses were not significantly different between both food challenges.Conclusion: The Diagnostic accuracy of open food challenge is non‐inferior to that of DBPCFC. This finding implies less demanding open food challenges can be implemented for children from the age of 4 years suspected to be cashew nut, hazelnut, or peanut allergic. Further research is necessary to validate our findings and to investigate the diagnostic accuracy for other major food allergens.
Open AccessComparison of Double‐Blind and Open Food Challenges for the Diagnosis of Food Allergy in Childhood: The ALDORADO Study
Background: Double‐blind placebo‐controlled food challenge (DBPCFC) is widely regarded as the “gold standard” to diagnose food allergy. Maximum efforts are made to reduce bias, yet DBPCFCs are costly, time‐, and resource‐intensive. Less demanding open food challenges are increasingly used in clinical practice. However, recommendations regarding the use of these challenges are based on low certainty of evidence, and no comparative studies have been performed using the most recent international food challenge guidelines. We hypothesised that the open food challenge is non‐inferior to DBPCFC in children suspected of allergy to cashew nuts, hazelnuts or peanuts.Methods: A total of 63 children, aged 4 years and older, were included if referred for suspected IgE‐mediated allergy to cashew nut, hazelnut, or peanut. All study participants underwent DBPCFC first, followed by an open food challenge for the same food. Challenge outcomes were assessed by predefined criteria into positive, negative, or inconclusive.Results: DBPCFC and open food challenge outcomes were the same for 36/41 (87.8%) patients. Sensitivity and specificity of the open food challenge were 0.91 (95% CI 0.79, 1.03) and 0.83 (95% CI 0.63, 1.01), respectively, with an AUC value of 0.87. Eliciting and stop doses were not significantly different between both food challenges.Conclusion: The Diagnostic accuracy of open food challenge is non‐inferior to that of DBPCFC. This finding implies less demanding open food challenges can be implemented for children from the age of 4 years suspected to be cashew nut, hazelnut, or peanut allergic. Further research is necessary to validate our findings and to investigate the diagnostic accuracy for other major food allergens.
- Open Access
- 19 January 2024
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 54 (3) , 216-218
Safe selection of children with a suspected food allergy to introduce peanut or tree nuts at home
- 19 January 2024
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 54 (3) , 216-218
Open AccessSafe selection of children with a suspected food allergy to introduce peanut or tree nuts at home
- Open Access
- 29 May 2023
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 53 (8) , 883-886
Investigation of novel salivary biomarkers in paediatric food allergy
- 29 May 2023
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 53 (8) , 883-886
Open AccessInvestigation of novel salivary biomarkers in paediatric food allergy
- Open Access
- 7 February 2022
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 10 (2) , 647-650
Corrections
- 7 February 2022
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 10 (2) , 647-650
Open AccessCorrections
- Open Access
- 16 November 2021
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 52 (1) , 201-204
Low health‐related quality of life is associated with declining home introduction of suspected food allergens
- 16 November 2021
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 52 (1) , 201-204
Open AccessLow health‐related quality of life is associated with declining home introduction of suspected food allergens
- Open Access
- 26 August 2021
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 33 (1) , e13654
The dilemma of open or double‐blind food challenges in diagnosing food allergy in children: Design of the ALDORADO trial
Background: It is of major importance to diagnose food allergy accurately. Current guidelines support the use of oral food challenges to do so. The double‐blind placebo‐controlled food challenge (DBPCFC) has been regarded as the ‘gold standard’ for decades. However, DBPCFCs are costly, and time‐ and resource‐intensive procedures. Structural implementation of less demanding open food challenges will only find support if research demonstrates that their outcome is comparable to DBPCFC, yet this has been proven difficult to investigate.Methods: We performed a literature review to investigate the diagnostic accuracy of oral food challenges and interviewed 19 parents of children with proven or suspected food allergy about the design of a trial to study this.Results: An overview of the dilemma of diagnosing food allergy using oral food challenges, and the methodological issues and parents’ opinions to study this. No comparative studies have been performed using the latest guidelines on oral food challenges.Conclusions: There is an urgent need to investigate the diagnostic accuracy of different oral food challenge protocols. We present the rationale and design of the ALDORADO trial (ALlergy Diagnosed by Open oR DOuble‐blind food challenge) that has been set up to investigate whether the outcome of the open food challenge is comparable to DBPCFC.
- 26 August 2021
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 33 (1) , e13654
Open AccessThe dilemma of open or double‐blind food challenges in diagnosing food allergy in children: Design of the ALDORADO trial
Background: It is of major importance to diagnose food allergy accurately. Current guidelines support the use of oral food challenges to do so. The double‐blind placebo‐controlled food challenge (DBPCFC) has been regarded as the ‘gold standard’ for decades. However, DBPCFCs are costly, and time‐ and resource‐intensive procedures. Structural implementation of less demanding open food challenges will only find support if research demonstrates that their outcome is comparable to DBPCFC, yet this has been proven difficult to investigate.Methods: We performed a literature review to investigate the diagnostic accuracy of oral food challenges and interviewed 19 parents of children with proven or suspected food allergy about the design of a trial to study this.Results: An overview of the dilemma of diagnosing food allergy using oral food challenges, and the methodological issues and parents’ opinions to study this. No comparative studies have been performed using the latest guidelines on oral food challenges.Conclusions: There is an urgent need to investigate the diagnostic accuracy of different oral food challenge protocols. We present the rationale and design of the ALDORADO trial (ALlergy Diagnosed by Open oR DOuble‐blind food challenge) that has been set up to investigate whether the outcome of the open food challenge is comparable to DBPCFC.
- 24 October 2013
- Published by Springer Nature in JGZ Tijdschrift voor jeugdgezondheidszorg
- Vol. 45 (5) , 104
Preventie, diagnostiek en behandeling van koemelkallergie, onderdeel van de JGZ-richtlijn Voedselovergevoeligheid
- 24 October 2013
- Published by Springer Nature in JGZ Tijdschrift voor jeugdgezondheidszorg
- Vol. 45 (5) , 104
Preventie, diagnostiek en behandeling van koemelkallergie, onderdeel van de JGZ-richtlijn Voedselovergevoeligheid
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa2071 Galectin-9 Induced by Dietary Synbiotics is Involved in Suppression of Allergic Symptoms in Mice and Humans
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa2071 Galectin-9 Induced by Dietary Synbiotics is Involved in Suppression of Allergic Symptoms in Mice and Humans